VP
venBio Partners Portfolio holdings
AUM
$115M
This Quarter Return
-10.77%
1 Year Return
-33.99%
3 Year Return
+221.07%
5 Year Return
+224.54%
10 Year Return
–
AUM
$1.05B
AUM Growth
+$1.05B
(-7.1%)
Cap. Flow
+$64.1M
Cap. Flow
% of AUM
6.09%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
8
New
1
Increased
–
Reduced
1
Closed
–
Top Buys
| 1 |
Pharvaris
PHVS
|
$64.4M |
Top Sells
| 1 |
VRNA
Verona Pharma
VRNA
|
$311K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
ALX Oncology
ALXO
$62.7M
| $715M | 67.97% | 9,699,925 | – | – |
|
2
Harmony Biosciences
HRMY
$2.12B
| $116M | 11% | 3,504,624 | – | – |
|
3
Akero Therapeutics
AKRO
$3.74B
| $70.9M | 6.74% | 2,444,311 | – | – |
|
|
4
Pharvaris
PHVS
$1.39B
| $64.4M | 6.12% | +2,303,310 | New | +$64.4M |
|
|
CMPI
5
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
| $44.6M | 4.24% | 3,673,374 | – | – |
|
6
Apellis Pharmaceuticals
APLS
$3.48B
| $21M | 2% | 490,471 | – | – |
|
|
MTCR
7
DELISTED
Metacrine, Inc. Common Stock
MTCR
| $19M | 1.8% | 3,059,123 | – | – |
|
|
VRNA
8
Verona Pharma
VRNA
$9.16B
| $1.35M | 0.13% | 161,897 -37,178 | -19% | -$311K |
|